Replies to post #27186 on Cytodyn Inc (CYDY)

[finesand]

Compilation Update + Catalyst Calendar

Update Log,

2019-01-15 - Pro 140 Publications, Patents & Statistics (updated),

2019-01-14 - Updated Model (draft), previous 2019-01-03 - Evaluation Model,

2018-07-22 - Comparison HIV-1 Anti-infective antibodies (needs update),

2018-06-26 - Pro 140 Metastatic Cancer Suppression,

2018-06-19 - The return of PRO 140, a CCR5-directed mAb,

2018-06-14 - Pro 140 Covering Scientists,

2018-06-23 - Insider Ownership,

2018-06-22 - PRO 140 SC Combo about to arrive,

2018-02-20 - Pro 140 Phase 2b/3 Pivotal PE Achieved,

Calendar from January 2019 Presentation, PRs & Notes

Pro 140 Important Milestones for HIV & Cancer 2019
- DONE: CD02 Pivotal Phase 3 Endpoint Achieved (ASM Microbe late breaker) (Source: CYDY)
- DONE: Full CD02 Trial Data Disclosure via 7/16 PR.
- DONE: Medical Conference Presentations (CROI and ASM Microbe) (Source: CYDY)
- DONE: Publication of Monotherapy (Phase 2b, CD01) (Source: CYDY)
- DONE: 150pt 24weeks 350mg safety data, 89 CD03 pts from 2017-10-17 completed on 2018-04-03 (7/17 CC + Deduction)
- DONE: Orphan Drug Designation for GvHD (ODD) granted by FDA (Source: CYDY)
- DONE: Published GvHD Preclinical Studies (Source: CYDY)
- DONE: Colon Cancer Animal Study Statistical Significant Results (8/15 CYDY PR)
- DONE: Complete Acquisition of ProstaGene (All share deal for Pestell&Co, how much?) (Source: CYDY)
- DONE: Colon Cancer Animal Study (Source: CYDY)
- DONE: CD03 Monotherapy 700mg w/ ~92% responder rate, 24/26 for 12 weeks, VL rebound (Source: CYDY)
- DONE: Triple Negative Breast Cancer (TNBC) Phase 1b/2 IND-Protocol filed & FDA approved (Source: CYDY)
- LATE: Publication Studies – CD02 Combo Primary Endpoint Study (Source: CYDY 7/19 CC)
- LATE: GvHD data review of 10(?) additional pts by iDMC soon (CYDY 7/19 CC)???
- 1Q19: Triple Negative Breast Cancer (TNBC) Pase 1b/2 first patient injected (Source: CYDY)
- 1Q19: Late Breaker at CROI - Combination therapy - Monotherapy - Will apply (Source: CYDY)
- 1H19: BLA Submission Completion (Source: CYDY)
- 1H19: Large Pharma discussion for potential licensing or partnering (Source: CYDY)
- 1H19: Triple Negative Breast Cancer (TNBC) Pase 1b/2 interim results (Source: CYDY)
- 1H19: IND-Protocol for colon cancer Phase 2 (Source: CYDY)
- 2019: Prognostic test licensed (Source: CYDY)
- 2020: Revenue potential of about $480M (Source: CYDY)

+++

Latest PR & Social Media

CYDY Published three interview updates

- 2019-01-14 Potential Breakthroughs, CYDY is Working Towards in HIV and Cancer Treatment – audio copy on youtube
-- $180M raised, only 10-15% more required for BLA submission
-- “mechanism working for any cancer that has CCR5, will be effective”
-- “50% of the breast cancer that metastasized have CCR5”
-- “The (cancer) market for such product could be in trillions, not billions, but trillions”, said Pourhassan
-- “non-dilutive fundraising is around the corner people in Europe are asking for Pro 140 .. to use it in the trial .. they want to collaborate with us they want to use Pro 140 as a sustaining mechanism… they are talking about licensing for the HIV and cancer with smaller and bigger pharma”, said Pourhassan
- 2019-01-11 CytoDyn aims to be ‘paradigm-shifting’ in cancer management with its platform drug leronlimab
- 2019-01-07 Monoclonal antibody HIV treatment w potential FDA approval in 2019

+++